Xtant Medical Holdings, Inc. (XTNT)
| Previous Close | 0.8900 |
| Open | 0.8861 |
| Bid | 0.8704 x 1800 |
| Ask | 0.8797 x 1400 |
| Day's Range | 0.8751 - 0.8797 |
| 52 Week Range | 0.6000 - 1.4500 |
| Volume | |
| Avg. Volume | 156,079 |
| Market Cap | 114.552M |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | 87.97 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% y
- GlobeNewswire
Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host
- GlobeNewswire
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company’s term loan was also amended to provide for an additional $10.0 million tranche, to be made available f
